Wondering what’s on tap at ISPOR’s European conference this year? ISPOR Europe 2024, scheduled for 17-20 November in Barcelona, Spain, will offer a robust program including plenaries and spotlights, HEOR Theaters, symposia, posters, exhibits, and more. Download and view the preliminary schedule today and begin planning your conference experience! https://ow.ly/JvXQ50Su8Ev #ISPOREurope #HEOR #healthcare #RWE #HTA Follow the HEOR Conferences LinkedIn page for updates on all ISPOR events>> https://lnkd.in/ga79mAav
ISPOR—The Professional Society for Health Economics and Outcomes Research
Hospitals and Health Care
Lawrenceville, NJ 35,425 followers
Improving healthcare decisions
About us
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
- Website
-
http://www.ispor.org
External link for ISPOR—The Professional Society for Health Economics and Outcomes Research
- Industry
- Hospitals and Health Care
- Company size
- 11-50 employees
- Headquarters
- Lawrenceville, NJ
- Type
- Nonprofit
- Founded
- 1995
- Specialties
- HEOR, Health Economics, Outcomes Research, and Health Economics and Outcomes Research
Locations
-
Primary
505 Lawrence Square Blvd South
Lawrenceville, NJ 08648, US
Employees at ISPOR—The Professional Society for Health Economics and Outcomes Research
-
Jessica Santos
Navigating complex regulatory, privacy and ethics landscape in healthcare as global compliance and quality director at Oracle Life Sciences…
-
Mikkel Z. Oestergaard
Senior Director at MSD | Co-Chair of Global Differential Pricing initiative at ISPOR | Strategic Advisor on Access to Medicines at the Max Foundation
-
Hélène Karcher, PhD
Global Pharma Executive | Access | Evidence Generation | Health Economics | Artificial Intelligence & Data Science
-
Amy O'Sullivan
Updates
-
Welcome to the new leadership of ISPOR’s Asia Consortium and Latin America Consortium whose terms began this month! Consortia are ISPOR regional groups that consist of ISPOR chapters and individual members interested in #HEOR within their region. https://ow.ly/zAxS50Su7un #ISPORian
-
-
Did you know the HEOR Learning Lab™ is an educational resource for professionals who work or have an interest in the field of health economics and outcomes research (HEOR)? This resource provides unlimited, on-demand, educational video content to facilitate learning and innovative approaches in the field from the leading global organization in HEOR. See what’s new in the HEOR Learning Lab today! https://ow.ly/5QJh50Su6tr #HEOR #healthcare Follow the HEOR Conferences LinkedIn page for updates on all ISPOR events>> https://lnkd.in/ga79mAav
-
-
#ISPORNews ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making. Learn more: https://ow.ly/FVEi50SxLsj
-
-
Not an ISPOR—The Professional Society for Health Economics and Outcomes Research member? #DYK participation in Member Groups is a member exclusive benefit? Join ISPOR today to get involved with Task Forces, Special Interest Groups, Councils, or as a Chapter Leader. https://ow.ly/V8bU50Sx5mx #MembershipMonday #Benefits #HEOR #Leadership #Volunteers
-
-
ISPOR’s Special Interest Groups provide members with a platform to focus on their specific areas of interest in health economics and outcomes research. These groups develop scientific and educational work products, monitor trends, and disseminate information to members. Learn more and get involved here>> https://ow.ly/xeLA50SrLME #HEOR #healthcare Follow the HEOR Conferences LinkedIn page for updates on all ISPOR events>> https://lnkd.in/ga79mAav
-
-
*NEW ISSUE* #ValueinHealthRegionalIssues featuring ✔️Ibrutinib improves CLL survival; cost-effectiveness debated. ✔️Reimbursement regulation delays access to innovative medical devices in Taiwan. Full issue ➡️https://ow.ly/fOJO50SuVZz . Follow us for featured stories & updates!
-
-
*NEW ISSUE* #ValueinHealth themed section "From Health to Welfare" on different facets of economic evaluation aimed to incorporate well-being beyond traditional health outcomes into decision making. Full issue ➡️ https://ow.ly/eT6Y50SuVkP. Follow us for featured stories & updates!
-
-
ISPOR welcomes the following members to the 2024-2025 Board of Directors: Elisabeth Fenwick, PhD, MSc, Chief Science Officer, Open Health Group, London, England, UK; Ramiro Gilardino, MD, MHS, Global HTA & Access Policy Lead at Global Access Department, MSD International, Zurich, Switzerland; Daniel Ollendorf, PhD, Chief Scientific Officer and Director of HTA Methods and Engagement, Institute for Clinical and Economic Review, Boston, MA, USA; Katja Rudell, PhD, MSc, Senior Director, Parexel International, London, England, UK. #HEOR https://ow.ly/ccHu50St8fO
-
-
As they end their terms, ISPOR thanks the following members of the Board of Directors for their dedicated service to the Society: Beth Devine (2021-2024) of The Comparative Health Outcomes, Policy and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, Washington, USA; Marlene Glydmark (2021-2024) of Idorsia Pharmaceuticals, Ltd., Basel, Switzerland; Andrea Manca (2021-2024) of Centre for Health Economics at the University of York, York, England, UK; Dong-Churl Suh (2021-2024) of Chung-Ang University College of Pharmacy, Seoul, South Korea. #HEOR https://ow.ly/NRjK50St7L0
-